CP-4055

What CP-4055 Means in Everyday Medical Language

CP-4055 is a chemotherapy drug used to treat advanced acute myeloid leukemia (AML), a type of blood cancer. It is also known by the names Elacyt and Elacytarabine. This drug is a modified form of cytarabine, a common chemotherapy medicine for leukemia. CP-4055 works by blocking cell division, which can help kill cancer cells and slow the growth of leukemia.

Why CP-4055 Can Matter in Cancer Care

Some leukemia cells become resistant to cytarabine, meaning the usual treatment may stop working well. CP-4055 was developed to help in these cases. Because it is a form of cytarabine that may still work when resistance occurs, it offers another option for patients with advanced AML. This can be important when doctors are looking for effective treatments after other medicines have not worked.

What Patients Might See or Hear About CP-4055

Patients may come across the term CP-4055, Elacyt, or Elacytarabine in medical reports, treatment plans, or discussions with their care team. It might be mentioned as part of chemotherapy options or clinical trials. Because the drug has several names, it can be confusing. Patients might hear that it is related to cytarabine but designed to work differently. It’s important to ask the care team how this drug fits into the overall treatment plan and what to expect.

Where CP-4055 Might Appear

CP-4055 can appear in medical records, treatment plans, clinical trial descriptions, or drug information pages. It may be listed as a treatment option for advanced AML, especially when leukemia is resistant to standard cytarabine therapy. Seeing the term in a report or note does not automatically mean it is part of a patient’s current treatment—it may be under consideration or part of research.

Common Sources of Confusion and How to Read CP-4055 in Context

Because CP-4055 is also called Elacyt or Elacytarabine, patients may find different names in their records or information sources. This can cause confusion. Also, since it is related to cytarabine, patients might wonder if it is the same drug or something new. The key is to understand that CP-4055 is a modified form designed to work when cytarabine alone may not be effective. Always ask the care team what the term means in your specific case rather than assuming it applies broadly.

Safety and Practical Advice

This information is educational and does not decide what is safe or appropriate for any individual patient. Treatment decisions depend on many factors, including overall health, cancer type, and response to therapy. If CP-4055 appears in your medical records or discussions, the best next step is to ask your care team to explain what it means for your care. They can provide personalized information about how this drug fits into your treatment plan and what to expect.